Effect of Chondroitin Sulfate on Blood Serum Cytokine Profile during Carrageenan-induced Edema and Monoiodoacetate-induced Osteoarthritis in Rats

Author(s): Oleksandr Korotkyi*, Andrii Vovk, Oksana Blokhina, Kateryna Dvorshchenko, Tetyana Falalyeyeva, Ludovico Abenavoli, Liudmyla Ostapchenko.

Journal Name: Reviews on Recent Clinical Trials

Volume 14 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Blood cytokines affect the development of inflammatory processes in both normal and pathological states. We have studied changes in the concentration of interleukins (ILs) - 1β, IL-4, IL-10, IL-12B p40, transforming growth factor β (TGF β), tumor necrosis factor (TNF-α) in acute carrageenan-induced inflammation and degenerative-dystrophic changes of knee joint caused by monoiodoacetate-induced Osteoarthritis (OA) in experimental models on rats. We also investigated the change in the cytokine profile during prophylactic and therapeutic administration of chondroitin sulfate to animals under experimental conditions.

Methods: The concentration of the cytokines was measured in blood serum by enzyme-linked immunosorbent assay.

Results: The manifestation of articular lesions was characterized by a disturbance in the balance between proinflammatory (IL-1β, IL-12B p40, TNF-α) and anti-inflammatory (IL-4, IL-10, TGF -β) cytokines.

Conclusion: A reduction in the concentration of proinflammatory cytokines in blood serum after prophylactic and therapeutic administration of chondroitin sulfate to the rat with experimental models of acute inflammation of the hind limb and degenerative-dystrophic changes in the knee joint with OA is associated with anti-inflammatory and regenerative properties of the drug.

Keywords: Cartilage disorders, experimental model of inflammation, interleukin, transforming growth factor, tumor necrosis factor, chondroitin sulfate.

[1]
March L, Smith EU, Hoy DG, et al. Burden of disability due to musculoskeletal (MSK) disorders. Best Pract Res Clin Rheumatol 2014; 28(3): 353-66.
[2]
Carlesso LC, Segal NA, Curtis JR, et al. Knee pain and structural damage as risk factors for incident widespread pain: Data from the multicenter osteoarthritis study. Arthritis Care Res 2017; 69(6): 826-32.
[3]
Man GS, Mologhianu G. Osteoarthritis pathogenesis - a complex process that involves the entire joint. J Med Life 2014; 7(1): 37-41.
[4]
Galvez I, Torres-Piles SD, Hinchado M, et al. Immune-neuroendocrine dysregulation in patients with osteoarthritis: A revision and a pilot study. Endocr Metab Immune Disord Drug Targets 2017; 17(1): 78-85.
[5]
Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther Adv Musculoskelet Dis 2013; 5(2): 77-94.
[6]
Orlowsky EW, Kraus VB. The role of innate immunity in osteoarthritis: When our first line of defense goes on the offensive. J Rheumatol 2015; 42(3): 363-71.
[7]
Abenavoli L, Pete V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9(3): 134-40.
[8]
Mabey T, Honsawek S. Cytokines as biochemical markers for knee osteoarthritis. World J Orthop 2015; 6(1): 95-105.
[9]
Muzzarelli RA, Greco F, Busilacchi A, Sollazzo V, Gigante A. Chitosan, hyaluronan and chondroitin sulfate in tissue engineering for cartilage regeneration: A review. Carbohydr Polym 2012; 89(3): 723-39.
[10]
Ishimaru D, Sugiura N, Akiyama H, et al. Alterations in the chondroitin sulfate chain in human osteoarthritic cartilage of the knee. Osteoarthritis Cartilage 2014; 22(2): 250-8.
[11]
Morris CJ. Carrageenan-induced paw edema in the rat and mouse. Methods Mol Biol 2003; 225: 115-21.
[12]
Jacobs BY, Dunnigan K, Pires-Fernandes M, Allen KD. Unique spatiotemporal and dynamic gait compensations in the rat monoiodoacetate injection and medial meniscus transection models of knee osteoarthritis. Osteoarthritis Cartilage 2017; 25(5): 750-8.
[13]
Baragi VM, Becher G, Bendele AM, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009; 60(7): 2008-18.
[14]
Towbin H, Schmitz A, Van Oostrum J, et al. Monoclonal antibody based enzyme-linked and chemiluminescent assays for the human interleukin-1 receptor antagonist. Application to measure hIL-1 receptor antagonist levels in monocyte cultures and synovial fluids. J Immunol Methods 1994; 170(1): 125-35.
[15]
Collett D. Modelling survival data in medical research CRC Press 2015: 3; 520
[16]
Luzina IG, Keegan AD, Heller NM, et al. Regulation of inflammation by interleukin-4: A review of “alternatives”. J Leukoc Biol 2012; 92: 753-64.
[17]
Amanvermez R, Gunay M, Piskin A, Keles G, Tomak L. TNF-α, IL-1β, and oxidative stress during fracture healing. Bratisl Lek Listy 2013; 114(11): 621-4.
[18]
Li ZC, Han N, Li X, et al. Decreased expression of microRNA-130a correlates with TNF-α in the development of osteoarthritis. Int J Clin Exp Pathol 2015; 8(3): 2555-64.
[19]
Moelants EA, Mortier A, Van Damme J, Proost P. Regulation of TNF-α with a focus on rheumatoid arthritis. Immunol Cell Biol 2013; 91(6): 393-401.
[20]
Kosek E, Altawil R, Kadetoff D, et al. Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain--interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritis. J Neuroimmunol 2015; 280: 49-55.
[21]
Zhao L, Ye J, Wu GT, et al. Gentiopicroside prevents interleukin-1 beta induced inflammation response in rat articular chondrocyte. J Ethnopharmacol 2015; 172: 100-7.
[22]
Pope RM, Shahrara S. Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat Rev Rheumatol 2013; 9(4): 252-6.
[23]
Croxford AL, Kulig P, Becher B. L-12-and IL-23 in health and disease. Cytokine Growth Factor Rev 2014; 25(4): 415-21.
[24]
Hilgenberg E, Shen P, Dang VD, et al. Interleukin-10-producing B cells and the regulation of immunity. Curr Top Microbiol Immunol 2014; 380: 69-92.
[25]
Harsini S, Ziaee V, Maddah M, et al. Interleukin 10 and transforming growth factor beta 1 gene polymorphisms in juvenile idiopathic arthritis. Bratisl Med J 2016; 117(5): 258-62.
[26]
Trifunović J, Miller L, Debeljak Ž, Horvat V. Pathologic patterns of interleukin 10 expression--a review. Biochem Med (Zagreb) 2015; 25(1): 36-48.
[27]
Van Meegeren MER, Roosendaal G, Jansen NW, et al. IL-4 alone and in combination with IL-10 protects against blood-induced cartilage damage. Osteoarthritis Cartilage 2012; 20(7): 764-72.
[28]
Van Meegeren MER, Roosendaal G, Van Veghel K, et al. A short time window to profit from protection of blood-induced cartilage damage by IL-4 plus IL-10. Rheumatology 2013; 52: 1563-71.
[29]
Venkatesha SH, Dudics S, Acharya B, Moudgil KD. Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci 2014; 16(1): 887-906.
[30]
Martel-Pelletier J, Farran A, Montell E, et al. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules 2015; 20(3): 4277-89.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 1
Year: 2019
Page: [50 - 55]
Pages: 6
DOI: 10.2174/1574887113666181102111247
Price: $58

Article Metrics

PDF: 21
HTML: 3